Potential peptides in atherosclerosis therapy

Front Horm Res. 2014:43:93-106. doi: 10.1159/000360568. Epub 2014 Jun 10.

Abstract

Atherosclerosis is the main underlying cause of ischemic heart disease and related acute cardiovascular complications, including myocardial infarction and stroke. In view of the failure of statins to demonstrate a beneficial effect in all patients, exhaustive research efforts have unfold into different research avenues, in close relation to the increase in basic knowledge regarding lipoprotein metabolism, macrophage function and inflammatory conditions associated with atherosclerosis. This review focuses specifically on potential therapeutic peptides targeting dyslipidemia, macrophage scavenger receptors, cholesterol metabolism and anti-inflammatory cytokines as novel therapeutic avenues in atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Apolipoprotein A-I / therapeutic use*
  • Apolipoproteins E / therapeutic use*
  • Atherosclerosis / drug therapy*
  • Dyslipidemias / drug therapy
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypolipidemic Agents / therapeutic use*
  • Intracellular Signaling Peptides and Proteins / physiology
  • Proprotein Convertase 9
  • Proprotein Convertases / antagonists & inhibitors
  • Serine Endopeptidases

Substances

  • Anti-Inflammatory Agents
  • Apolipoprotein A-I
  • Apolipoproteins E
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Intracellular Signaling Peptides and Proteins
  • humanin
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases